IN8bio (NASDAQ:INAB) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of IN8bio (NASDAQ:INAB) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock.

IN8bio Price Performance

Shares of IN8bio stock opened at $0.31 on Tuesday. The firm has a market capitalization of $22.47 million, a PE ratio of -0.41 and a beta of -0.07. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. IN8bio has a 12 month low of $0.22 and a 12 month high of $2.48. The business’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.64.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Sell-side analysts forecast that IN8bio will post -0.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp increased its stake in shares of IN8bio, Inc. (NASDAQ:INAB) by 42.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the quarter. Sigma Planning Corp owned approximately 1.82% of IN8bio worth $230,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 92.05% of the stock is currently owned by institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.